| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1191/0961203303LU389OA |
| P698 | PubMed publication ID | 12892388 |
| P50 | author | Yehuda Shoenfeld | Q1515807 |
| Munther A. Khamashta | Q73418907 | ||
| Takao Koike | Q73731383 | ||
| Ronald H. W. M. Derksen | Q73744763 | ||
| Pier Luigi Meroni | Q38544871 | ||
| Angela Tincani | Q73304219 | ||
| Jean-Charles Piette | Q73305204 | ||
| P2093 | author name string | J A McIntyre | |
| M Moia | |||
| J M M C Arnout | |||
| P2860 | cites work | Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome | Q28182136 |
| Managing oral anticoagulant therapy | Q30649541 | ||
| Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study | Q33338827 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. | Q33342481 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment | Q33565796 | ||
| Recurrent venous thromboembolism: diagnosis and management | Q33982493 | ||
| Hemorrhagic complications of anticoagulant treatment | Q34131093 | ||
| Antithrombotic therapy for venous thromboembolic disease | Q34131105 | ||
| Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
| Hypercoagulability syndromes | Q34432158 | ||
| Duration of anticoagulation for venous thromboembolism | Q34441615 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| Warfarin for venous thromboembolism - walking the dosing tightrope | Q44324811 | ||
| The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants | Q45867213 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
| P433 | issue | 7 | |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| venous thromboembolism | Q9397786 | ||
| P304 | page(s) | 504-507 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis | |
| P478 | volume | 12 |
| Q95359130 | Q95359130 |
| Q33415287 | Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin |
| Q43901099 | Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients |
| Q58602902 | Antiphospholipid syndrome: state of the art on clinical practice guidelines |
| Q28222458 | Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up |
| Q37076800 | Controversies in the antiphospholipid syndrome: can we ever stop warfarin? |
| Q46770296 | Idiopathic intracranial hypertension: associations with thrombophilia and hypofibrinolysis in men. |
| Q37107209 | Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome. |
| Q45771233 | Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study |
| Q33361019 | Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation |
| Q36969463 | The cost-benefit ratio of screening pregnant women for thrombophilia |
| Q33365607 | The systemic nature of the antiphospholipid syndrome |
| Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
Search more.